A Phase 2 interventional study of Apilimod Dimesylate Capsule and Placebo in COVID-19 Disease, sponsored by OrphAI Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-08.
Sponsored by OrphAI Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,860 studies in COVID-19 with a site in United States, this one is the 548th largest by enrollment of the 1,322 interventional ones that give a count, is one of 818 that started in 2020, is one of 350 in phase 2, and was the 478th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,860 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 482 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 92 across the 1,322 interventional studies, 300 across the 521 observational. Of the 1,415 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,860 have an industry lead sponsor. The 10 most frequent:
OrphAI Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.
OrphAI Therapeutics has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
84 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,860 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
This is a Phase II randomized, double-blind, placebo-controlled, clinical study to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standard supportive care in an outpatient setting.
Study eligibility will be assessed during screening. All study participants must sign a written informed consent and satisfy the inclusion and exclusion criteria for the study. Confirmation of SARS-CoV-2 infection, medical history, and current medication will be assessed for each consenting participant at screening.
Study participants will be randomized in a 1:1 ratio, to receive study therapy (either LAM-002A, 125 mg [5 capsules/dose]) PO BID or placebo [5 capsules/dose] PO BID) for 10 days. Participants who experience an adverse event (AE) considered to be related to study therapy may have a decrease in study dose of LAM-002A to 100 mg [4 capsules/dose]) PO BID or placebo [4 capsules/dose] PO BID). After the start of treatment on Day 1, participants will be followed at Days 4,6,8,11,22, and 28. Days 6,8, and 22 will be phone visits. Participants can withdraw from the study therapy or study participation at any time.
The study will incorporate an interim safety analysis after the first 30 participants (15 on LAM-002A and 15 on placebo) have completed treatment and have been followed up for 11 days post-first dose. Recruitment and randomization will continue while this analysis is conducted. Recommendations from an independent Data Safety Monitoring Board (DSMB) will be used for decisions of early termination or study design adaptations.
Non-parametric and parametric statistical analysis will be conducted, as appropriate. For the comparison of the LAM-002A active arm and the control arm for the primary endpoint and secondary endpoints of drug effect, appropriate methods will be employed. Baseline subject characteristics, study therapy administration/compliance, safety, supportive care administration, and pharmacokinetics will be analyzed descriptively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hepatic profile showing any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days
Drug: Apilimod Dimesylate Capsule
(microcrystalline cellulose) in 5 capsules BID for 10 days
Other: Placebo
LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
Microcrystalline cellulose in Swedish orange, Size 0 capsules
Viral Load Change
The primary efficacy outcome measure evaluated change in SARS-CoV-2 viral load at Day 4 from Day 1, of LAM-002A or placebo-treated participants. SARS-CoV-2 viral load was measured by a real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) test of nasopharyngeal samples. Analysis focused on log10 viral load on Day 4 compared to baseline viral load at Day 1 in participants with baseline viral load \>100,000 copies/mL
Time frame: 4 Days
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
The number and percentage of LAM 002A-treated participants who developed TEAEs compared to placebo
Time frame: 28 Days
Clinical Efficacy
Number of Participants with Hospitalization or Death within 28 days
Time frame: 28 Days
Change in COVID-19 Clinical Status
To evaluate change in COVID-19 clinical status, as defined by the ordinal scale, of participants treated with LAM-002A compared to placebo at Day 28, in participants who became hospitalized and continued LAM-002A/placebo treatment, based on the following scores: 1. Not in the hospital 2. Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula) 3. Hospitalized, not on invasive ventilation (such as 100% non-rebreather, BIPAP), (pre-ICU) 4. Hospitalized, in the ICU, on invasive ventilation or Extracorporeal membrane oxygenation (ECMO) 5. Dead
Time frame: 28 Days
Oxygen Saturation
Comparison of the number and percentage of participants with an oxygen saturation (O2 sat) ≥95% between LAM-002A versus placebo treatment groups.
Time frame: Baseline, Day 1, Day 4, Day 11, Day28
Number and Percentage of Participants With Viral Load < Lower Limit of Quantification (LLOQ)
Evaluated the difference in the number and percentage of participants with a SARS-CoV-2 viral load \<LLOQ between the LAM-002A and the placebo arm as measured by a qRT-PCR test from nasopharyngeal samples at Day 4.
Time frame: 4 Days
This study was conducted by 8 investigators located at medical centers throughout the United States
| Milestone | LAM-002A | Placebo |
|---|---|---|
| Started | 71 | 71 |
| Completed | 64 | 66 |
| Not completed | 7 | 5 |
| Withdrew: Withdrawal by subject | 6 | 1 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Not eligible | 0 | 1 |
The primary efficacy outcome measure evaluated change in SARS-CoV-2 viral load at Day 4 from Day 1, of LAM-002A or placebo-treated participants. SARS-CoV-2 viral load was measured by a real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) test of nasopharyngeal samples. Analysis focused on log10 viral load on Day 4 compared to baseline viral load at Day 1 in participants with baseline viral load \>100,000 copies/mL
| log10 copies/mL | LAM-002A | Placebo |
|---|---|---|
| Viral Load Change | -2.50 ± 2.35 | -1.99 ± 1.71 |
The number and percentage of LAM 002A-treated participants who developed TEAEs compared to placebo
| Participants | LAM-002A | Placebo |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 26 | 14 |
Number of Participants with Hospitalization or Death within 28 days
| Participants | LAM-002A | Placebo |
|---|---|---|
| Yes | 2 | 1 |
| No | 69 | 70 |
To evaluate change in COVID-19 clinical status, as defined by the ordinal scale, of participants treated with LAM-002A compared to placebo at Day 28, in participants who became hospitalized and continued LAM-002A/placebo treatment, based on the following scores: 1. Not in the hospital 2. Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula) 3. Hospitalized, not on invasive ventilation (such as 100% non-rebreather, BIPAP), (pre-ICU) 4. Hospitalized, in the ICU, on invasive ventilation or Extracorporeal membrane oxygenation (ECMO) 5. Dead
| Participants | LAM-002A | Placebo |
|---|---|---|
| 1: Not in the hospital | 64 | 66 |
| 2: Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula) | 0 | 0 |
| 3: Hospitalized, not on invasive ventilation (such as 100% non-rebreather, BIPAP), (pre-ICU) | 0 | 0 |
| 4: Hospitalized, in the ICU, on invasive ventilation or ECMO | 0 | 0 |
| 5: Dead | 0 | 0 |
| Status Unknown* | 7 | 5 |
Comparison of the number and percentage of participants with an oxygen saturation (O2 sat) ≥95% between LAM-002A versus placebo treatment groups.
| Participants | LAM-002A | Placebo |
|---|---|---|
| Baseline, oxygen saturation ≥95% — Yes | 67 | 68 |
| Baseline, oxygen saturation ≥95% — No | 4 | 3 |
| Day 1, oxygen saturation ≥95% — Yes | 60 | 59 |
| Day 1, oxygen saturation ≥95% — No | 2 | 2 |
| Day 4, oxygen saturation ≥95% — Yes | 59 | 65 |
| Day 4, oxygen saturation ≥95% — No | 9 | 3 |
| Day 11, oxygen saturation ≥95% — Yes | 60 | 65 |
| Day 11, oxygen saturation ≥95% — No | 4 | 2 |
| Day 28, oxygen saturation ≥95% — Yes | 65 | 66 |
| Day 28, oxygen saturation ≥95% — No | 0 | 0 |
Evaluated the difference in the number and percentage of participants with a SARS-CoV-2 viral load \<LLOQ between the LAM-002A and the placebo arm as measured by a qRT-PCR test from nasopharyngeal samples at Day 4.
| Participants | LAM-002A | Placebo |
|---|---|---|
| Number and Percentage of Participants With Viral Load < Lower Limit of Quantification (LLOQ) | 9 | 3 |
Collected over Adverse events were collected from the first administration of study drug through Day 28 or when any ongoing drug-related adverse events (AEs) and/or serious adverse events (SAEs) resolved or became stable, up to 30 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LAM-002A | 1/71 (1.4%) | 2/71 (2.8%) | 26/71 (36.6%) |
| Placebo | 0/70 (0%) | 1/70 (1.4%) | 15/70 (21.4%) |
| Event | LAM-002A | Placebo |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/71 | 1/70 |
| COVID-19 pneumoniaInfections and infestations | 1/71 | 0/70 |
| Event | LAM-002A | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/71 | 5/70 |
| NauseaGastrointestinal disorders | 7/71 | 3/70 |
| VomitingGastrointestinal disorders | 4/71 | 2/70 |
| DizzinessNervous system disorders | 3/71 | 0/70 |
| AstheniaGeneral disorders | 0/71 | 2/70 |
| PyrexiaGeneral disorders | 0/71 | 2/70 |
| Feeling abnormalGeneral disorders | 2/71 | 1/70 |
| SinusitisInfections and infestations | 2/71 | 0/70 |
| HeadacheNervous system disorders | 2/71 | 1/70 |
| LethargyNervous system disorders | 2/71 | 0/70 |
The intention-to-treat (ITT) population included all participants randomized according to their initial randomized assignment regardless of the treatment actually received.
| Age, Continuous(years) | LAM-002A | Placebo | Total |
|---|---|---|---|
| Median | 42.8 (18.7 to 70.4) | 43.3 (18.5 to 65.7) | 43.1 (18.5 to 70.4) |
| Sex: Female, Male(Participants) | LAM-002A | Placebo | Total |
|---|---|---|---|
| Female | 37 | 37 | 74 |
| Male | 34 | 34 | 68 |
| Ethnicity (NIH/OMB)(Participants) | LAM-002A | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 27 | 52 |
| Not Hispanic or Latino | 45 | 44 | 89 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | LAM-002A | Placebo | Total |
|---|---|---|---|
| Patient Race — White | 64 | 61 | 125 |
| Patient Race — Black or African American | 2 | 7 | 9 |
| Patient Race — Asian | 3 | 0 | 3 |
| Patient Race — Other | 0 | 1 | 1 |
| Patient Race — Unknown | 2 | 2 | 4 |
| Region of Enrollment(participants) | LAM-002A | Placebo | Total |
|---|---|---|---|
| United States | 71 | 71 | 142 |
| ECOG Performance Status(Participants) | LAM-002A | Placebo | Total |
|---|---|---|---|
| 0: Fully active | 55 | 59 | 114 |
| 1: Restricted | 16 | 11 | 27 |
| 2: Ambulatory | 0 | 1 | 1 |
| Oxygen Saturation(percent) | LAM-002A | Placebo | Total |
|---|---|---|---|
| Median | 98.0 (95.0 to 100.0) | 98.0 (95.0 to 100.0) | 98.0 (95.0 to 100.0) |
| Temperature(degrees Celsius) | LAM-002A | Placebo | Total |
|---|---|---|---|
| Median | 36.8 (35.7 to 38.6) | 36.8 (35.6 to 38.0) | 36.8 (35.6 to 38.6) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Mar 2021, 8 months.
Results were first posted in Aug 2023, 2 years 4 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 8 months is close to that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apilimod Dimesylate Capsule
OrphAI Therapeutics